Prof. Yan Xiaoyu

About me

Yan Xiaoyu 閆曉宇

Assistant Professor
School of Pharmacy
Faculty of Medicine
The Chinese University of Hong Kong

Tel: (852) 3943 5012
Fax:(852) 2603 5295

Personal Details

Xiaoyu Yan received his Bachelor’s and Master’s degree from Shenyang Pharmaceutical University, China. He also received a Master’s degree in pharmaceutical sciences from University of Saskatchewan, Canada. He obtained his PhD in 2012 from Department of Pharmaceutical Sciences, University at Buffalo (SUNY). After his PhD, he worked as a clinical pharmacometrician/pharmacologist at Janssen Research & Development (Johnson & Johnson) and Regeneron Pharmaceuticals, USA.

During his time in pharmaceutical industry, Xiaoyu applied model informed drug development approaches to help the development team not only better understand disease and target, but also find the right dose for the right patient at right time. He has contributed to the global approval of several new therapies for diseases in various areas, such as oncology, immunology, cardiovascular, and neuroscience.

Xiaoyu joined the School of Pharmacy at the Chinese University of Hong Kong in September 2018. His research interests are focused on the pharmacokinetics and pharmacodynamics of therapeutic biologics, and utilization of modeling and simulation approaches to optimize drug therapy and develop new treatment strategy.

***Xiaoyu’s group has openings for postdoctoral fellows, MPhil/PhD students, research assistants, visiting scholars. Candidates with a background in relative areas (biochemistry/molecular biology, pharmacology, cell biology, immunology, biochemical engineering, drug metabolism and pharmacokinetics, mathematics, statistics or other field related) are welcome to apply. Please contact Dr. Yan ( for more information.***


Research Interests

Xiaoyu’s current research is focused on the development of new therapies for anemic patients demonstrating resistance to erythropoiesis-stimulating agents (ESAs). ESAs is a class of therapeutic proteins functioning as erythropoietin receptor (EPOR) agonists. They stimulate the production of red blood cells by binding to EPOR on erythroid cells in bone marrow, and stimulate their proliferation and differentiation.

ESAs has transformed the way of managing the anemia in patients with chronic kidney disease (CKD), who may need blood transfusion otherwise. Recombinant human erythropoietin (rHuEPO) is the first approved ESA by US FDA in 1989 to treat anemia associated with CKD. However, up to 10% of anemic patients failed to show a satisfactory response to rHuEPO, and still require blood transfusion eventually. This phenomenon was named EPO resistance. The EPO resistance is also associated with increased risk of death or cardiovascular events.

Xiaoyu’s previous work suggested the rHuEPO treatment can induce erythroid precursor pool depletion, which may contribute to EPO resistance. Accordingly, his current work is to further the understanding role of precursor depletion in EPO resistance, and look for new therapeutic strategy that may alleviate rHuEPO induced precursor depletion. This work may provide new treatment option for anemic patients showing EPO resistance, and reduce their transfusion burden.



  • PHAR5130 Overview of Drug Development
  • PHAR2220 Biopharmaceutics and Pharmacokinetics
  • GENA1113 General Education


Representative Publications

(* Corresponding author)

  1. Zou H, Zhang Y, Zhong D, Jiang Y, Liu F, Zho Q, Zuo Z, Zhang Y, Yan X*. Effect of autoinduction and food on the pharmacokinetics of furmonertinib and its active metabolite characterized by a population pharmacokinetic model. Acta Pharmacologica Sinica. 2021 Nov 17. doi: 10.1038/s41401-021-00798-y.
  2. Yan X, Bauer R, Koch G, Schropp J, Perez Ruixo JJ, Krzyzanski W. Delay differential equations based models in NONMEM. J Pharmacokinet Pharmacodyn 2021 Dec;48(6):763-802. doi: 10.1007/s10928-021-09770-z
  3. Yan X, Tse AHW, Lee A, Zhang L, Yang M, Zuo Z, Joynt  GM. Protein Binding and Population Pharmacokinetics of Dexmedetomidine after Prolonged Infusions in Adult Critically Ill Patients. Clin Ther. 2021 Jul 22;S0149-2918
  4. Nguyen LM, Li Z, Yan X, Krzyzanski W. A quantitative systems pharmacology model of hyporesponsiveness to erythropoietin in rats. J Pharmacokinet Pharmacodyn. 2021 Jun 7. doi: 10.1007/s10928-021-09762-z.
  5. Li Z, Yuanfeng Lyu Y, Zhao J, Li D, Lin Z, To KKW, Yan X, Zuo Z. Disease status dependent drug-herb interactions: NASH lowered the risk of hepatotoxicity in rats co-administered with simvastatin and Gardenia jasminoides. Front. Pharmacol., 2021 Apr 23;12:622040. doi: 10.3389/fphar.2021.622040.
  6. Zhao J, Cheng SW, Ng WL, Zhang Y, Shek TL, Ren T, Yan X, Li K, Wang J, Zuo Z. Identification of the in vivo relevant dissolution media for the three active components in EGb 761 tablet for better correlation with their pharmacokinetics in healthy subjects. Eur J Pharm Sci. 2020;154:105515.
  7. Li Z, Zhang J, Zhang Y, Zhou L, Zhao J, Lyu Y, Poon LH, Lin Z, To KKW, Yan X, Zuo Z. Intestinal absorption and hepatic elimination of drugs in high-fat high-cholesterol diet-induced non-alcoholic steatohepatitis rats: exemplified by simvastatin. Br J Pharmacol 2020 doi:10.1111/bph.15298
  8. Yao X, Yan X, Wang X, Cai T, Zhang S, Cui C, Wang X, Hou Z, Liu Q, Li H, Lin J, Xiong Z, Liu D. Population-based meta-analysis of chloroquine: informing chloroquine pharmacokinetics in COVID-19 patients. Eur J Clin Pharmacol. 2020 doi:10.1007/s00228-020-03032-6. (Co-first author)
  9. Zou H, Banerjee P, Leung SSY, Yan X*. Application of Pharmacokinetic-Pharmacodynamic Modeling in Drug Delivery: Development and Challenges. Front. Pharmacol., 2020 Jul 3;11:997. doi: 10.3389/fphar.2020.00997.
  10. Yan X*, Xu SX*, Weisel KC, et al. Early M-protein Dynamics Predicts Progression-Free Survival in Patients With Relapsed/Refractory Multiple Myeloma. Clin Transl Sci. 2020 Nov;13(6):1345-1354

More Publications

Supplementary Information


  • Janssen R&D, Innovation Leadership Awards, 2016
  • Janssen R&D, Innovation Leadership Awards, 2015
  • Janssen R&D, Innovation Leadership Awards, 2014
  • McKeen Cattell Memorial Award, American College of Clinical Pharmacology (ACCP) Recognition Award, Washington, DC 2013
  • American Society for Clinical Pharmacology & Therapeutics (ASCPT) Presidential Trainee Award, ASCPT Annual Meeting, Indianapolis, IN 2013
  • Graduate Student Symposium Award PPDM/CPTR, American Association of Pharmaceutical Scientists (AAPS) Annual Meeting, Washington, DC, 2011
  • Travel Award by AAPS Executive Council, AAPS Annual Meeting, New Orleans, LA, 2010
  • Pfizer Canada Centennial Pharmacy Research Award, Saskatoon, Canada 2006

Professional Memberships

  • American Association of Pharmaceutical Scientists
  • American College of Clinical Pharmacology
  • International Society of Pharmacometrics (ISoP)
  • American Society Clinical Pharmacology & Therapeutics

Comments are closed